Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00011986 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,312
- Enrollment target
NCT00011986 is a Phase 3 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 4,312 participants.
The verdict
NCT00011986, a Phase 3 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,312 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have stage III or stage IV ovarian cancer or primary peritoneal cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Gemcitabine Hydrochloride
- DRUG Topotecan Hydrochloride
- DRUG Pegylated Liposomal Doxorubicin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,312 participants |
| Start Date | 2001-01 |
| Est. Completion | 2013-01-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00011986
The ClinicalTrials.gov registry entry for NCT00011986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00011986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00011986 about?
NCT00011986 is a clinical study titled "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and peritoneal cancer. Randomized phase III trial to compare the effectivene...
What is the current status of trial NCT00011986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,312 participants. The study started on 2001-01. Estimated completion is 2013-01-28.
What interventions are being tested in trial NCT00011986?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Gemcitabine Hydrochloride (DRUG), Topotecan Hydrochloride (DRUG), Pegylated Liposomal Doxorubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00011986?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.